Biocon's biosimilar subsidiary is valued at $3.5bn in the deal, which will involve Tata Capital acquiring a stake sized at under 1%.

Nestlé is the main backer of the consumer investment firm's latest fund, which has a $150m target for its final close.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UCL Technology Fund 2 has achieved a first close on the way to its $131m target, with a cornerstone investment from UCL itself.

Axa Investment Managers was among the participants in a $13.9m round for Alydia, which is developing a system to treat postpartum haemorrhage.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

There are occasional silver linings even for the blackest clouds. One was as the Covid-19 disease broke out this year competition for deals became a little lighter.

Omega Therapeutics is firing up preclinical development of an epigenomic drug platform invented at Whitehead Institute and incubated by Flagship Pioneering.

Nura Bio is working on neuroprotective treatments that exploit discoveries made at OHSU and UT Southwestern.

Tech Launch Arizona has crossed the milestone of 100 spinouts in its portfolio after achieving a new annual record in the 2019-2020 fiscal year.